HLA-A3-restricted melanoma-associated peptide-MHC class I complex (HLA-A3 pMHC)

HLA-A3-restricted melanoma-associated peptide-MHC class I complexes are specialized molecular assemblies found on the surface of melanoma cells that present intracellular tumor antigens to the adaptive immune system (Source: UniProt P01889). These complexes consist of a Human Leukocyte Antigen-A3 (HLA-A3) heavy chain, beta-2 microglobulin, and a short peptide fragment derived from melanoma-specific proteins such as MAGE-A3, gp100, or tyrosinase (Source: Gaugler et al., J Exp Med, 1994). Their primary biological role is to serve as a ligand for T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, signaling the presence of malignant cells and triggering an immune response (Source: Kawakami et al., PNAS, 1994). In oncology, these complexes are exploited as highly specific therapeutic targets for TCR-engineered T-cell therapies and bispecific T-cell engagers designed to redirect the immune system to eliminate tumors (Source: Robbins et al., J Clin Oncol, 2011). Effective targeting requires patients to possess the HLA-A*03 allele and for their tumors to express the relevant melanoma antigen, making this a cornerstone of precision immunotherapy. However, a significant therapeutic challenge is the risk of off-target toxicity if the engineered TCR cross-reacts with similar peptide sequences found in healthy tissues (Source: Linette et al., Blood, 2013). Despite these challenges, targeting HLA-A3 complexes significantly expands the reach of TCR-based therapies beyond the more commonly targeted HLA-A2 allele.

Other names

HLA-A*03:01-peptide complexMelanoma-associated pMHC-A3 complexHLA-A3-restricted tumor antigen complexpMHC class I HLA-A3

The mechanism of action involves the high-affinity recognition of the specific peptide-HLA-A3 epitope by an engineered T-cell receptor (TCR). This binding event induces the formation of an immunological synapse, leading to T-cell activation, the release of cytotoxic granules (perforin and granzymes), and the subsequent apoptotic lysis of the melanoma cell (Source: Stone et al., Analyst, 2012).